Elanco Animal Health Incorporated Gain (Loss) on Disposition of Assets
Elanco Animal Health Incorporated (ELAN) reported Gain (Loss) on Disposition of Assets of $51.30 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-07-30.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2020-07-30
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for the quarter ending 2020-06-30 was $47.50M.
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for the quarter ending 2020-03-31 was $3.80M.
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for the quarter ending 2019-06-30 was $0.00.
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for the quarter ending 2019-03-31 was $0.00.
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for fiscal 2018 was $800.00K, a 95.92% decline from fiscal 2017.
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for fiscal 2017 was $19.60M.
- Elanco Animal Health Incorporated gain (loss) on disposition of assets for fiscal 2016 was $0.00.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2020-06-30 | $47.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $51.30M 10-Q · filed 2020-07-30 | ||
| 2020-03-31 | $3.80M 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-02-28 | |||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $0.00 10-Q · filed 2020-07-30 | $800.00K derived: sum of 3 quarters · filed 2020-07-30 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $800.00K derived: sum of 2 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $800.00K 10-K · filed 2020-02-28 | ||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | |||
| 2017-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $19.60M 10-K · filed 2020-02-28 | ||
| 2017-09-30 | $16.00M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |